Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E (including mixed tocopherols and tocotrienols) has been studied for its potential to reduce certain side effects of chemotherapy, particularly chemotherapy-induced peripheral neuropathy (CIPN), a common and sometimes debilitating complication of drugs like cisplatin, paclitaxel, and oxaliplatin. The rationale is that Vitamin E acts as an antioxidant, potentially protecting nerve cells from the oxidative stress and damage induced by chemotherapy agents. Several small randomized controlled trials and meta-analyses have assessed this potential benefit. Some studies found that Vitamin E supplementation (typically 300-600 mg/day) may reduce the incidence or severity of CIPN, while others found no significant benefit. The quality of evidence is variable, with limitations including small sample sizes, heterogeneity in chemotherapy regimens, and inconsistent outcome measures. There is insufficient evidence to recommend Vitamin E for other chemotherapy side effects such as mucositis or cardiotoxicity. Major oncology guidelines do not currently endorse routine Vitamin E supplementation during chemotherapy, in part due to concerns that antioxidants could interfere with the efficacy of certain chemotherapeutic agents. In summary, while some preliminary evidence supports the use of Vitamin E to mitigate chemotherapy-induced neuropathy, the overall evidence base is limited and inconclusive, meriting a score of 2 out of 5.

More about Vitamin E (mixed tocopherols/tocotrienols)
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Vitamin E (mixed tocopherols/tocotrienols)

Products containing Vitamin E (mixed tocopherols/tocotrienols)